Last reviewed · How we verify

Allife Medical Science and Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Allife Medical Science and Technology Co., Ltd. pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 14 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AffyImmune Therapeutics, Inc. · 1 shared drug class
  2. Celgene · 1 shared drug class
  3. Chongqing Precision Biotech Co., Ltd · 1 shared drug class
  4. Hebei Senlang Biotechnology Inc., Ltd. · 1 shared drug class
  5. ImmunityBio, Inc. · 1 shared drug class
  6. Kite, A Gilead Company · 1 shared drug class
  7. Memorial Sloan Kettering Cancer Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Allife Medical Science and Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Allife Medical Science and Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allife-medical-science-and-technology-co-ltd. Accessed 2026-05-17.

Related